English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Patients with nonalcoholic steatohepatitis (NASH)-associated cirrhosis have the highest rates of major adverse liver outcomes (MALO) within the fatty liver disease spectrum and therefore have the highest unmet need for effective therapeutic agents. Several drugs are being tested for patients with NASH cirrhosis with different mechanisms of action and endpoints. This article summarizes the available data on the natural history of NASH cirrhosis and the rates of developing MALO. We provide examples of ongoing clinical trials for NASH cirrhosis including the study design and endpoints. We then discuss the FDA-guidance on acceptable endpoints for NASH cirrhosis trials that will lead to approval. Metabolic and antifibrotic drugs are currently in phase 2b trials for NASH cirrhosis with outcomes ranging from histologic improvement on liver biopsy to the development of varices or MALO. We provide the readers with pragmatic advice on trial design for phase 2B and 3 NASH cirrhosis trials. The data presented in the article justify further development and investigation of therapeutic agents for the treatment of NASH cirrhosis.

Nonalcoholic steatohepatitis (NASH) cirrhosis: a snapshot of therapeutic agents in clinical development and the optimal design for clinical trials